Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 507-514

  Baek, Hyunjung ^a,b   Uchida, Hiroaki ^c   Jun, Kyungok ^a   Kim, Jae Hong ^b   Kuroki, Masahide ^d   Cohen, Justus B ^c   Glorioso, Joseph C ^c   Kwon, Heechung ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea University   (South Korea)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTER PROTEIN; ADAPTOR PROTEIN; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN D; HERPESVIRUS VECTOR; NECTIN 1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CHO CELL; CONTROLLED STUDY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN BINDING; PROTEIN EXPRESSION; SOLID TUMOR; STOMACH CARCINOMA;

CRICETULUS GRISEUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 79952190298     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.207     Document Type: Article

References (53)

1. Spear, PG (2004). Herpes simplex virus (Pubitemid 38488933)
2. Campadelli-Fiume, G, Amasio, M, Avitabile, E, Cerretani, A, Forghieri, C, Gianni, T et al. (2007). The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol 17: 313-326. (Pubitemid 47425869)
3. Zhou, G and Roizman, B (2006). Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13α2 receptor. Proc Natl Acad Sci USA 103: 5508-5513.
4. Menotti, L, Cerretani, A, Hengel, H and Campadelli-Fiume, G (2008). Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 82: 10153-10161.
5. Menotti, L, Nicoletti, G, Gatta, V, Croci, S, Landuzzi, L, De Giovanni, C et al. (2009). Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA 106: 9039-9044.
6. Waehler, R, Russell, SJ and Curiel, DT (2007). Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8: 573-587. (Pubitemid 47077278)
7. Schaffer, DV, Koerber, JT and Lim, KI (2008). Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 10: 169-194.
8. Montgomery, RI, Warner, MS, Lum, BJ and Spear, PG (1996). Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87: 427-436. (Pubitemid 26374317)
9. Geraghty, RJ, Krummenacher, C, Cohen, GH, Eisenberg, RJ and Spear, PG (1998). Entry of α-herpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280: 1618-1620. (Pubitemid 28277708)
10. Krummenacher, C, Rux, AH, Whitbeck, JC, Ponce-de-Leon, M, Lou, H, Baribaud, I et al. (1999). The frst immunoglobulin-like domain of HveC is suffcient to bind herpes simplex virus gD with full affnity, while the third domain is involved in oligomerization of HveC. J Virol 73: 8127-8137. (Pubitemid 29441673)
11. Lopez, M, Cocchi, F, Avitabile, E, Leclerc, A, Adelaide, J, Campadelli-Fiume, G et al. (2001). Novel, soluble isoform of the herpes simplex virus (HSV) receptor nectin1 (or PRR1-HIgR-HveC) modulates positively and negatively susceptibility to HSV infection. J Virol 75: 5684-5691. (Pubitemid 32488163)
12. Whitbeck, JC, Peng, C, Lou, H, Xu, R, Willis, SH, Ponce de Leon, M et al. (1997). Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol 71: 6083-6093. (Pubitemid 27304949)
13. Nakano, K, Asano, R, Tsumoto, K, Kwon, H, Goins, WF, Kumagai, I et al. (2005). Herpes simplex virus targeting to the EGF receptor by a gD-specifc soluble bridging molecule. Mol Ther 11: 617-626. (Pubitemid 40353119)
14. Kwon, BS, Tan, KB, Ni, J, Oh, KO, Lee, ZH, Kim, KK et al. (1997). A newly identifed member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 272: 14272-14276. (Pubitemid 27232840)
15. Marsters, SA, Ayres, TM, Skubatch, M, Gray, CL, Rothe, M and Ashkenazi, A (1997). Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J Biol Chem 272: 14029-14032. (Pubitemid 27232801)
16. Manoj, S, Jogger, CR, Myscofski, D, Yoon, M and Spear, PG (2004). Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci USA 101: 12414-12421. (Pubitemid 39122038)
17. Hsu, H, Solovyev, I, Colombero, A, Elliott, R, Kelley, M and Boyle, WJ (1997). ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5. J Biol Chem 272: 13471-13474. (Pubitemid 27224772)
18. Hammarström, S (1999). The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9: 67-81. (Pubitemid 29265523)
19. Whitbeck, JC, Connolly, SA, Willis, SH, Hou, W, Krummenacher, C, Ponce de Leon, M et al. (2001). Localization of the gD-binding region of the human herpes simplex virus receptor, HveA. J Virol 75: 171-180.
20. Kwon, H, Bai, Q, Baek, HJ, Felmet, K, Burton, EA, Goins, WF et al. (2006). Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D. J Virol 80: 138-148.
21. Kuroki, M, Arakawa, F, Matsuo, Y, Oikawa, S, Misumi, Y, Nakazato, H et al. (1991). Molecular cloning of nonspecifc cross-reacting antigens in human granulocytes. J Biol Chem 266: 11810-11817. (Pubitemid 21907021)
22. Chen, X, Li, J, Mata, M, Goss, J, Wolfe, D, Glorioso, JC et al. (2000). Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J Virol 74: 10132-10141.
23. Krisky, DM, Marconi, PC, Oligino, T, Rouse, RJ, Fink, DJ and Glorioso, JC (1997). Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 4: 1120-1125. (Pubitemid 27469944)
24. Tsvitov, M, Frampton, AR Jr, Shah, WA, Wendell, SK, Ozuer, A, Kapacee, Z et al. (2007). Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology 360: 477-491. (Pubitemid 46482613)
25. Takai, Y and Nakanishi, H (2003). Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci 116: 17-27. (Pubitemid 36113961)
26. Simpson, SA, Manchak, MD, Hager, EJ, Krummenacher, C, Whitbeck, JC, Levin, MJ et al. (2005). Nectin-1/HveC mediates herpes simplex virus type 1 entry into primary human sensory neurons and fbroblasts. J Neurovirol 11: 208-218. (Pubitemid 40852428)
27. Uchida, H, Shah, WA, Ozuer, A, Frampton, AR Jr, Goins, WF, Grandi, P et al. (2009). Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identifcation of mutations that rescue nectin-1 recognition. J Virol 83: 2951-2961.
28. Tanaka, T, Huang, J, Hirai, S, Kuroki, M, Kuroki, M, Watanabe, N et al. (2006). Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fber-modifed adenovirus vectors. Clin Cancer Res 12: 3803-3813. (Pubitemid 44000262)
29. Desai, P and Person, S (1998). Incorporation of the green fuorescent protein into the herpes simplex virus type 1 capsid. J Virol 72: 7563-7568. (Pubitemid 28377889)
30. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
31. Wakimoto, H, Johnson, PR, Knipe, DM and Chiocca, EA (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 10: 983-990. (Pubitemid 36722433)
32. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS, Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887. (Pubitemid 29372413)
33. Bender, FC, Whitbeck, JC, Lou, H, Cohen, GH and Eisenberg, RJ (2005). Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol 79: 11588-11597. (Pubitemid 41279277)
34. Satoh, T, Arii, J, Suenaga, T, Wang, J, Kogure, A, Uehori, J et al. (2008). PILRα is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell 132: 935-944. (Pubitemid 351381742)
35. Laquerre, S, Anderson, DB, Stolz, DB and Glorioso, JC (1998). Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 72: 9683-9697. (Pubitemid 28520832)
36. Argnani, R, Boccafogli, L, Marconi, PC and Manservigi, R (2004). Specifc targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide. Gene Ther 11: 1087-1098. (Pubitemid 39023113)
37. Zhou, G, Ye, GJ, Debinski, W and Roizman, B (2002). Engineered herpes simplex virus 1 is dependent on IL13Rα 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 99: 15124-15129. (Pubitemid 35334620)
38. Fan, Q, Lin, E, Satoh, T, Arase, H and Spear, PG (2009). Differential effects on cell fusion activity of mutations in herpes simplex virus 1 glycoprotein B (gB) dependent on whether a gD receptor or a gB receptor is overexpressed. J Virol 83: 7384-7390.
39. Li, HJ, Everts, M, Pereboeva, L, Komarova, S, Idan, A, Curiel, DT et al. (2007). Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecifc adapter. Cancer Res 67: 5354-5361. (Pubitemid 46997275)
40. Würdinger, T, Verheije, MH, Broen, K, Bosch, BJ, Haijema, BJ, de Haan, CA et al. (2005). Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. J Virol 79: 15314-15322. (Pubitemid 43032313)
41. Ebbinghaus, C, Al-Jaibaji, A, Operschall, E, Schöffel, A, Peter, I, Greber, UF et al. (2001). Functional and selective targeting of adenovirus to high-affnity Fcγ receptor I-positive cells by using a bispecifc hybrid adapter. J Virol 75: 480-489.
42. Dmitriev, I, Kashentseva, E, Rogers, BE, Krasnykh, V and Curiel, DT (2000). Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 74: 6875-6884. (Pubitemid 30470671)
43. Kashentseva, EA, Douglas, JT, Zinn, KR, Curiel, DT and Dmitriev, IP (2009). Targeting of adenovirus serotype 5 pseudotyped with short fber from serotype 41 to c-erbB2-positive cells using bispecifc single-chain diabody. J Mol Biol 388: 443-461.
44. Roller, RJ and Rauch, D (1998). Herpesvirus entry mediator HVEM mediates cell-cell spread in BHK(TK-) cell clones. J Virol 72: 1411-1417. (Pubitemid 28116927)
45. Cocchi, F, Menotti, L, Dubreuil, P, Lopez, M and Campadelli-Fiume, G (2000). Cell-to-cell spread of wild-type herpes simplex virus type 1, but not of syncytial strains, is mediated by the immunoglobulin-like receptors that mediate virion entry, nectin1 (PRR1/HveC/HIgR) and nectin2 (PRR2/HveB). J Virol 74: 3909-3917. (Pubitemid 30180336)
46. Hemminki, A, Wang, M, Hakkarainen, T, Desmond, RA, Wahlfors, J and Curiel, DT (2003). Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Ther 10: 583-588. (Pubitemid 36988532)
47. Verheije, MH, Würdinger, T, van Beusechem, VW, de Haan, CA, Gerritsen, WR and Rottier, PJ (2006). Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. J Virol 80: 1250-1260. (Pubitemid 43134082)
48. Carette, JE, Graat, HC, Schagen, FH, Mastenbroek, DC, Rots, MG, Haisma, HJ et al. (2007). A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology 361: 56-67. (Pubitemid 46551227)
49. Niranjan, A, Wolfe, D, Tamura, M, Soares, MK, Krisky, DM, Lunsford, LD et al. (2003). Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 8: 530-542. (Pubitemid 37321681)
50. Krisky, DM, Marconi, PC, Oligino, TJ, Rouse, RJ, Fink, DJ, Cohen, JB et al. (1998). Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 5: 1517-1530. (Pubitemid 28517379)
51. Jiang, C, Ataai, M, Ozuer, A, Krisky, D, Wechuck, J, Pornsuwan, S et al. (2006). Inactivation of herpes simplex type 1 gene vector on immobilized metal affnity chromatography: oxidative damage by hydroxyl free radicals and its prevention. Biotechnol Bioeng 95: 48-57. (Pubitemid 44348619)
52. Liao, S, Khare, PD, Arakawa, F, Kuroki, M, Hirose, Y, Fujimura, S et al. (2001). Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein. Anticancer Res 21(3B): 1673-1680. (Pubitemid 32728899)
53. Kuroki, M, Arakawa, F, Haruno, M, Murakami, M, Wakisaka, M, Higuchi, H et al. (1992). Biochemical characterization of 25 distinct carcinoembryonic antigen (CEA) epitopes recognized by 57 monoclonal antibodies and categorized into seven groups in terms of domain structure of the CEA molecule. Hybridoma 11: 391-407.